Poorly organized tumour vasculature often results in areas of limited nutrient supply and hypoxia. Despite our understanding of solid tumour responses to hypoxia, how nutrient deprivation regionally affects tumour growth and therapeutic response is poorly understood. Here, we show that the core region of solid tumours displayed glutamine deficiency compared with other amino acids. Low glutamine in tumour core regions led to dramatic histone hypermethylation due to decreased α-ketoglutarate levels, a key cofactor for the Jumonji-domain-containing histone demethylases. Using patient-derived V600E BRAF melanoma cells, we found that low-glutamine-induced histone hypermethylation resulted in cancer cell dedifferentiation and resistance to BRAF inhibitor treatment, which was largely mediated by methylation on H3K27, as knockdown of the H3K27-specific demethylase KDM6B and the methyltransferase EZH2 respectively reproduced and attenuated the low-glutamine effects in vitro and in vivo. Thus, intratumoral regional variation in the nutritional microenvironment contributes to tumour heterogeneity and therapeutic response.
. Similar to glucose metabolism, increased glutamine uptake is controlled by oncogenes, such as c-MYC and KRAS [3] [4] [5] . On the other hand, as tumours grow, increased glutamine catabolism may deplete the local supply and lead to periods of glutamine deprivation. This is supported by in vivo studies where in numerous tumours, including hepatomas and sarcomas, glutamine falls to almost undetectable levels relative to normal tissues 6 . A recent study using metabolomics analysis comparing paired pancreatic tumour patient samples with benign adjacent tissue specimens revealed that glutamine is one of the most strongly depleted metabolites in tumours 7 . However, how low glutamine levels in solid tumours affects tumour growth and therapeutic response remains largely unknown.
Reversible histone lysine methylation controlled by a variety of histone methyltransferases (HMTs) and histone demethylases (HDMs) modulates chromatin structure and thereby contributes to a variety of cellular processes such as transcription, replication and repair 8 . A subset of HDMs named Jumonji-domain-containing (JmjC) HDMs (JHDMs) utilizes α-ketoglutarate (αKG), oxygen and Fe (II) as cofactors and releases succinate and formaldehyde as by-products 9 . The requirement for αKG in mediating histone demethylase activity implied a potential interplay between metabolism and epigenetic modification. For example, a recent report demonstrated that glutamine deprivation in embryonic stem cells leads to increased methylation on H3K27me3 and H3K9me3 10 . In addition, mutant forms of the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2, which display neomorphic functions by producing 2-hydroxyglutarate (2HG) from αKG (n = 5) * * * * * * * * 0 P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y 
Figure 1
Tumour core regions display low glutamine levels and hypermethylation of histone H3. (a) Tissues from periphery and core regions of xenograft tumours were homogenized and used for amino acid extraction. Glutamine concentration was determined by glutamine assay. Data represent mean ± s.d. from independent xenografts (Ras-3T3, n = 5; MDA-MB-231, n = 4; M229, n = 8; M249, n = 5). * P < 0.05, * * * P < 0.001 by unpaired two-tailed Student's t-test. (b) M229 xenograft tumours were harvested and separated into periphery and core samples. Metabolites were extracted from each sample and αKG concentration was measured by LC-MS. Data represent mean ± s.d., n = 6 tumours. * * * P < 0.001 by unpaired two-tailed Student's t-test. (c) 4 mM glutamine-or PBS controlinjected tumours were harvested. Metabolites were extracted from the core tissues; then αKG (left) and glutamine (right) concentrations were measured by LC-MS. Data represent mean ± s.d., n = 6 tumours. * * * P < 0.001 by unpaired two-tailed Student's t-test. Source data for a-c are shown in Supplementary Table 4 . (d) Tissues from periphery and core regions of xenograft tumours were used for histone extraction or lysed to collect wholecell lysate. Histone methylation levels and other proteins were assessed by western blotting with the specified antibodies. Total histone H3 and actin were used as loading controls. (e) Melanoma tumour tissues were harvested from transgenic (Tg) mice. Histone methylation levels in different tumours were assessed by western blotting. Total histone H3 and actin were used as loading controls. (f) Immunohistochemistry staining in xenograft tumours. Whole tumours were sliced and stained with antibodies against H3K9me3 and H3K27me3. Scale bar, 50 µm. (g) Photograph of the same M229 xenograft tumour before and after clearing (left; scale bars, 1.5 mm) and 3D imaging of the M229 xenograft tumour depicting DAPI nuclear staining (blue) and H3K27me3 antibody staining (red) (right; scale bar, 300 µm). Unprocessed original scans of blots are shown in Supplementary Fig. 8 .
whether low glutamine levels in solid tumours affect the activity of these αKG-dependent JHDMs and hence modulate histone methylation remains unclear.
In this study, we measured the extent of glutamine heterogeneity regionally within solid tumours, dissected the impact of low glutamine on tumour cell dedifferentiation and drug sensitivity, and mechanistically linked specific histone demethylation to the impact of microenvironmental glutamine levels on tumour cell plasticity. Our study provides important evidence that regional glutamine deficiency leads to dedifferentiation and drug resistance via inhibition of histone demethylation.
RESULTS
Tumour core regions display low glutamine levels and hypermethylation of histone H3 To assess potential differences in glutamine levels in the periphery versus core region of tumours, we dissected different tumour xenografts and measured the glutamine concentrations in these distinct intratumoral regions ( Supplementary Fig. 1a ). We found that glutamine concentrations were consistently and significantly lower in the tumour core regions compared with the tumour periphery (Fig. 1a) . We next measured the αKG level in the tumour tissues by liquid chromatography-mass spectrometry (LC-MS) analysis. As were lysed for histone extraction and histone lysine methylation levels were assessed by western blotting. Total histone H3 was used as a loading control.
(b) M229 cells were cultured in medium with different concentrations of glutamine as indicated for 4 days, then cells were lysed for histone extraction and histone lysine methylation levels were assessed by western blotting. Total histone H3 was used as a loading control. (c) Cells were cultured in complete medium, low-glutamine medium, or low glutamine plus 7 mM dimethyl-αKG for 4 days, then cells were lysed for histone extraction and histone lysine methylation levels were assessed by western blotting. Total histone H3 was used as a loading control. (d) Cells were cultured in different conditions as indicated, and then metabolites were extracted from the cells; αKG and glutamine concentrations were measured by LC-MS. Data represent mean ± s.d., n = 3 independent experiments. * * * P < 0.001 by unpaired twotailed Student's t-test. Source data are shown in Supplementary Table 4 .
(e) In complete medium, 2 mg ml −1 968-or 100-µM DON-treated M229 cells were lysed for histone extraction, and histone lysine methylation levels were assessed by western blotting. Total histone H3 was used as a loading control. (f) Metabolites were extracted from DON-treated M229 cells; then αKG and glutamine concentrations were measured by LC-MS. Data represent mean ± s.d. n = 3 independent experiments. * P < 0.05, * * * P < 0.001 by unpaired two-tailed Student's t-test. Unprocessed original scans of blots are shown in Supplementary Fig. 8 .
with glutamine, compared with the periphery regions, αKG levels were significantly decreased in the tumour cores (Fig. 1b) . Moreover, the αKG level was largely restored by injecting glutamine into the tumour cores, suggesting that glutamine is sufficient to maintain tumour αKG levels (Fig. 1c) . Since αKG is an essential cofactor for the JHDMs, we tested whether low glutamine levels in the tumour core regions correlated with differential histone methylation levels. At all of the histone H3 methylation sites, which are the targets of JHDMs [13] [14] [15] , histone methylation levels dramatically increased in the core region (Fig. 1d) . HIF-1α was used as a 'marker' of the core tissues as it is induced in the core region of solid tumours due to hypoxia 16 . In addition, KRAS expression was used to distinguish tumour tissues from tumour adjacent normal tissues. We further examined histone methylation using melanoma tumours spontaneously developed from mice carrying a Braf tm1Mmcm /Pten tm1Hwu allele 17 . Similarly, increased histone methylation was found in the core regions compared with the periphery in tumours from transgenic mice (Fig. 1e) .
In addition, histone hypermethylation in the tumour core regions was also confirmed by immunohistochemistry staining using an antibody against H3K27me3 or H3K9me3 (Fig. 1f) . Moreover, we directly visualized H3K27me3 levels in intact tumours using the recently established technology for intact, slice-free, whole-tissue imaging and phenotyping, PACT (defined as Passive CLARITY) 18 ( Supplementary Fig. 1b ). In agreement with western blot and IHC analysis, H3K27me3 staining significantly increased in the melanoma tumour core regions (Fig. 1g) . Furthermore, HIF-1α and H3K27me3 staining strongly overlapped ( Supplementary Fig. 1c ). Thus, low glutamine and high histone methylation levels commonly coexist in the core regions of tumours. Tumour cores often contain extensive dead cells. Despite the increased cell death ( Supplementary  Fig. 1d,e) , there were still a certain amount of live cells in the tumour cores as cells in tumour cores could be stained by Ki67 antibody and displayed a negative staining of cleaved caspase-3 ( Supplementary Fig. 1c,d ).
Low glutamine level leads to increased histone methylation in tumour cells Next we determined whether increased histone methylation in tumour core regions was induced by glutamine deficiency. We found that low glutamine was sufficient to induce histone hypermethylation, particularly on Lys9, Lys27 and Lys36, in both a time-and dosedependent manner (Fig. 2a,b) . Moreover, histone hypermethylation required 0.2 mM for melanoma cells (Fig. 2b) , which was similar to the glutamine concentration in tumour core regions (Fig. 1a) . Furthermore, cell-permeable dimethyl-αKG was sufficient to prevent low-glutamine-induced histone methylation in all tumour cell types tested (Fig. 2c) , suggesting that increased histone methylation induced by low glutamine levels resulted from low αKG. As a control, intracellular glutamine and αKG under these conditions were also measured (Fig. 2d) . Furthermore, melanoma cells treated with the glutaminase inhibitors DON and compound 968 (refs 19,20) also displayed increased histone methylation (Fig. 2e) . As expected, DON treatment led to an 80% decreased αKG level (Fig. 2f) . Interestingly, we found that the glutamine level decreased by 40% following DON treatment. In addition, to understand whether the cell proliferation rate had any effect on histone methylation, we examined H3 lysine methylation in confluent cells and observed no increase in histone methylation as compared with cells cultured in low glutamine ( Supplementary  Fig. 2a ). Furthermore, cell number and cell survival were assayed under these conditions, but no correlation between cell proliferation and histone methylation was found ( Supplementary Fig. 2b,c) .
Glutamine deficiency drives histone hypermethylation in tumour core regions To assess the extent of selectivity of nutritional deficiency in the core regions of tumours, we measured the concentration of all amino acids in the core versus peripheral regions by LC-MS. Interestingly, only the levels of five amino acids (including glutamine) were significantly lower in the core relative to the peripheral regions (Table 1) , and this result was confirmed again by another independent metabolomics analysis (Supplementary Table 1) . We further determined which relative amino acid deficiency was most responsible for increased histone methylation using medium that contained the corresponding concentration of each decreased amino acid (although the levels in cell culture may drop quickly due to consumption) and found that only low glutamine levels resulted in increased histone methylation (Fig. 3a) . In addition, we found that histone methylation was induced only when glutamine was low, but not under a combinatorial deficiency of the other four amino acids (arginine, serine, aspartic acid and asparagine; Supplementary Fig. 3a) . Moreover, other forms of metabolic stress had no significant effect on histone methylation levels ( Fig. 3b and Supplementary Fig. 3b ). Interestingly, the combination of low glutamine and hypoxia resulted in greater histone methylation than either alone, particularly on H3K4me3, suggesting that hypoxia is not the only mechanism contributing to this phenomenon in solid tumours (Fig. 3b) .
Moreover, we found that a glutaminase inhibitor, compound 968, led to dramatic histone methylation in the tumour periphery, with levels similar to the core region of control-treated tumours (Fig. 3c) . Using PACT we found that, in contrast to the untreated tumour in Fig. 1g , 968-treated tumour displayed higher levels of H3K27me3 M229 xenograft tumours were harvested and separated into periphery and core samples (n = 3 biologically independent xenografts). Metabolites were extracted from each sample and used for LC-MS analysis. The mean value of each amino acid concentration (µM) and core/periphery ratio are shown. The P value was calculated by unpaired two-tailed Student's t-test.
methylation in both tumour periphery and core regions (Fig. 3d ).
In addition, increased histone methylation was largely attenuated by intratumour injections of glutamine, particularly on H3K9 and H3K27 (Fig. 3e ). Taken together, these data demonstrate that low levels of glutamine are the major contributor to increased histone methylation in the tumour core regions.
Low glutamine leads to dedifferentiation in tumour cores
Previous reports indicate that histone hypermethylation induced by IDH mutants prevents cell differentiation via inhibiting αKG-dependent histone demethylases 12 . Therefore, we examined whether decreased αKG in low-glutamine conditions can affect cell differentiation using two adipocyte models, human adipocyte-derived stem cells (ADSCs) and 3T3-L1 cells. Interestingly, we found that cells cultured in low glutamine failed to differentiate compared with cells cultured in complete medium (Fig. 4a) . In melanomas, markers for dedifferentiation have been identified such as CD271, CD133 and ABCB5 [21] [22] [23] [24] . Differentiation markers in melanomas have also been reported, such as ERBB3, KIT, PMEL and GJB [25] [26] [27] [28] [29] . Next, we performed RNASeq and compared the genes related to melanoma dedifferentiation and differentiation in core versus periphery regions. Consistent with the result that low glutamine inhibited adipocyte differentiation, we found that dedifferentiation-related genes were upregulated while differentiation genes were downregulated in the tumour core regions compared with matched peripheral regions (Fig. 4b ). This finding in xenograft tumours was further corroborated by the upregulation of a panel of dedifferentiation genes in melanoma cells cultured under low-glutamine conditions (Fig. 4c,e) , while the differentiation genes are simultaneously downregulated ( Fig. 4d and Supplementary Fig. 4a ). In addition, low-glutamine-induced temporal CD271 expression paralleled P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e Figure 3 Glutamine deficiency drives histone hypermethylation in tumour core regions. (a) M229 cells were cultured in complete medium and the medium with specified concentrations (which are similar to the concentration in tumour cores) of select amino acids for 4 days, then cells were lysed for histone extraction and histone lysine methylation levels were assessed by western blotting. Total histone H3 was used as a loading control. (b) M229 cells were cultured under the conditions indicated for 4 days, then cells were lysed for histone extraction and histone lysine methylation levels were assessed by western blotting. EAA, essential amino acid; Glc, glucose. Total histone H3 was used as a loading control. (c) Control and 968-treated xenograft tumours were harvested. Tissues from the periphery and core regions were lysed for histone extraction and histone lysine methylation levels were assessed by western blotting. Total histone H3 and actin were used as loading controls. (d) 3D imaging of an M229 xenograft tumour treated with 968 depicting DAPI (blue) and H3K27me3 antibody (red) staining. Scale bar, 300 µm. (e) 4 mM glutamine-or PBS control-injected tumours were harvested. Tissues from the periphery and core regions were lysed for histone extraction and histone lysine methylation levels were assessed by western blotting. Total histone H3 was used as a loading control. Unprocessed original scans of blots are shown in Supplementary Fig. 8 .
the dose response and time course of low-glutamine-induced histone hypermethylation ( Fig. 4g versus 2b , and Fig. 4h versus 2a) . To further distinguish whether low glutamine leads to dedifferentiation or selectively expands a small subpopulation of cells that already carry the signatures, we sorted and collected CD133/CD271 double-negative (CD133 − /CD271 − ) cells ( Supplementary Fig. 4b,c) . We then cultured these cells in low glutamine followed by flow cytometry analysis and found that a large portion of the previously CD271 − /CD133 − cells now expressed CD271 and CD133 (Fig. 4f) . Consistently, H3 lysine methylation and CD271 expression level increased in these cells after glutamine starvation (Supplementary Fig. 4d ). In addition, CD271 expression was specifically induced by deficiency of glutamine but not other amino acids (Fig. 4i) , which could be reversed by adding dimethyl-αKG or glutamine back in the medium (Fig. 4j) . As expected, the expression of CD271 was increased in the core region of solid tumours, and compound 968 treatment induced CD271 expression also in the periphery of tumours (Fig. 4k,l) .
Low-glutamine-induced dedifferentiation results in resistance to BRAF inhibitor treatment
We then assessed whether glutamine-deficiency-induced dedifferentiation would impact responses to targeted therapies. First, we found P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e POU5F1  ABCB5  SOX8  WNT5A  WNT9A  FOXD3  MYC  NOTCH1  ID1  NOTCH2  NGFR  WNT2B  NES  SNAI2  WNT7B  WNT5B  ID2  ETS1  WNT11  ID3  NOTCH3  WNT6 (k) Tissues from periphery and core regions of M249 xenograft tumours were lysed to collect whole-cell lysate. Protein levels were assessed by western blotting with specified antibodies. (l) Control and 968-treated M229 xenograft tumours were harvested. Tissues from the periphery and core regions were lysed and protein levels were assessed by western blotting with specified antibodies. Unprocessed original scans of blots are shown in Supplementary Fig. 8 .
that V600E BRAF melanoma cells maintained over 80% viability in low glutamine (0.1 mM) or low glucose (5-30% of complete medium) ( Fig. 5a and Supplementary Fig. 3c ). Compared with melanoma cells in complete medium, cells proliferated at a slower rate in medium containing 0.1 mM glutamine or in 30% glucose (Fig. 5b) . Interestingly, we found that melanoma cells cultured in low glutamine before BRAF treated with different doses of PLX4032 for 72 h. MTS assay was performed to measure cell viability. Data represent mean ± s.d., n = 3 independent cell cultures for M229; n = 4 for M249. * * * P < 0.001 by unpaired twotailed Student's t-test. (d) M229 and M249 cells were cultured in complete, 0.1 mM glutamine or 30% glucose (7.5 mM) medium for 4 days, and then treated with 1 µM PLX4032 for 24, 48 or 72 h. MTS assay was performed to measure cell viability. Data represent mean ± s.d., n = 4 independent cell cultures. * * * P < 0.001 by unpaired two-tailed Student's t-test. Source data are shown in Supplementary Table 4 .
inhibitor, PLX4032, treatment were less sensitive to the drug compared with those cultured in complete medium (Fig. 5c ). Although cells displayed a similar proliferation rate under low-glutamine or lowglucose conditions, we found only the low-glutamine condition resulted in drug resistance, but not the low-glucose condition (Fig. 5d) . These data correlated with the previous observation that only low glutamine, but not low-glucose conditions, induced hypermethylation of histones (Fig. 3b) .
Low-glutamine-induced dedifferentiation is mediated by histone methylation on H3K27
We next investigated whether low-glutamine-induced cell dedifferentiation is mediated by histone hypermethylation. We found that global histone methylation inhibitors, including Adox and DZNep 30, 31 , reversed low-glutamine-induced CD271 expression (Fig. 6a) . Furthermore, an inhibitor targeting H3K27me3, EPZ005687 (ref. 32), suppressed the low-glutamine-induced CD271 expression to a similar extent as the global inhibitors. In contrast, H3K9 inhibitors BRD4770 (ref. 33 ) and UNC0638 (ref. 34 ) had no effect on lowglutamine-induced CD271 expression ( Fig. 6a and Supplementary  Fig. 5a,b) . These data suggest that tri-methylation on H3K27 plays a major role in low-glutamine-induced melanoma tumour cell dedifferentiation. Consistently, the H3K27me3 methylation inhibitor EPZ005687 prevented low-glutamine-induced methylation on H3K27 and CD271 expression in a dose-dependent manner ( Supplementary  Fig. 5c ) as well as the expression of dedifferentiation genes in general (Fig. 6b) . To further confirm that changes in CD271 expression were dependent on H3K27 methylation, we knocked down KDM6B, a H3K27-specific demethylase, and observed a dramatic induction of H3K27 methylation and CD271 expression in cells cultured in complete medium (Fig. 6c) . Next, we knocked down EZH2, the H3K27 methyltransferase in melanoma cells and found that cells cultured in 0.1 mM glutamine medium with EZH2 knockdown failed to induce methylation on H3K27me3 and CD271 expression ( Fig. 6d and Supplementary Fig. 6a,b) . Importantly, the knockdown effect of EZH2 short hairpin RNAs (shRNAs) could be rescued by overexpression , n = 9 biologically independent RNA extracts. * * * P < 0.001 by unpaired two-tailed Student's t-test. CD271 and H3K27me3 levels were measured by western blotting (right). (e,f) After transduction of lentiviral EZH2 shRNA, cells were cultured in complete or 0.1 mM glutamine for at least 4 days, and then RNA was extracted from bulk M229 cells, and dedifferentiation-(e) and differentiation-(f) related gene expression was checked by qPCR. Data represent mean ± s.d., n = 3 biologically independent RNA extracts. * P < 0.05, * * P < 0.01, * * * P < 0.001 by unpaired two-tailed Student's t-test. (g) Cells were cultured in complete or 0.1 mM glutamine medium for 4 days, and then cells were harvested for ChIP assay using antibody against H3K27me3. Immunoprecipitation of the neural differentiation-related gene promoters (GJB1 and DCT in M229, PMEL and KIT in M249) were analysed by qPCR. Data represent mean ± s.d., n = 3 independent experiments. * P < 0.05, * * * P < 0.001 by unpaired two-tailed Student's t-test. Source data are shown in Supplementary Table 4 . Unprocessed original scans of blots are shown in Supplementary Fig. 8 .
of an shRNA-resistant EZH2 complementary DNA in the melanoma cells ( Supplementary Fig. 6a,b) . Consistently, we found the induction of dedifferentiation genes by low glutamine was dramatically blocked by EZH2 knockdown (Fig. 6e) . As H3K27me3 functions to suppress transcriptional activation, we next examined whether H3K27me3 plays a role in inhibiting expression of differentiation genes. First, suppression of differentiation markers in low-glutamine medium was reversed by treating cells with H3K27me3 methylation inhibitor EPZ005687 ( Supplementary Fig. 5d ,e) or knocking down EZH2 (Fig. 6f) . Chromatin immunoprecipitation (ChIP) analysis using antibodies against H3K27me3 revealed that differentiation genes are directly repressed by this H3K27me3 methylation marker at the promoter regions (Fig. 6g) . Besides JmjC family histone demethylases, there are other αKG-dependent enzymes such as HIF1-α prolyl-hydroxylase (HIF-PH) and TET enzymes that promote DNA demethylation. Knockdown of HIF-1α had no effect on histone hypermethylation in low-glutamine conditions ( Supplementary Fig. 7a,b) . Moreover, whole-genome DNA methylation sequencing found no significant differences between complete-and low-glutamine-cultured melanoma cells (Supplementary Fig. 7c) , and DNA methylation inhibitors 5-azacytidine and 5-aza-2 -deoxycytidine failed to inhibit CD271 induction in 0.1 mM glutamine medium (Supplementary Fig. 7d ).
Low-glutamine-induced drug resistance is mediated by histone methylation on H3K27
We next tested whether low-glutamine-induced resistance to BRAF inhibitor, PLX4032, was mediated by hypermethylation of H3K27. Melanoma cells cultured in low glutamine displayed resistance to PLX4032, but this effect was prevented when the global histone demethylase inhibitor DZNep or the H3K27-methylation-specific inhibitor EPZ005687 was supplemented in the low-glutamine condition (Fig. 7a) . In addition, knockdown of the H3K27-specific demethylase, KDM6B, which resulted in increased CD271 expression (Fig. 6c) , led to resistance to PLX4032 treatment compared with the control cells (Fig. 7b) . On the other hand, the protective effect against PLX4032 treatment in low-glutamine conditions was reduced after knockdown of the H3K27 methyltransferase EZH2 (Fig. 7c) . Finally, we performed a mouse xenograft experiment using melanoma cells and treated the mice with PBS control, DZNep, PLX4032, or the combination of DZNep and PLX4032. We found that treatment with PLX4032 alone inhibited tumour growth, especially at early time points; however, when combined with DZNep, PLX4032 treatment led to dramatic decreases in tumour size (Fig. 7d) . As expected, histone methylation was attenuated in the DZNep and PLX4032 combination-treated tumour core regions (Fig. 7e) . Interestingly, no impairment in tumour growth was found following DZNep treatment, suggesting that it may take a long time (more than 10 weeks) to see the significant effects on tumour growth 35 . We also observed similar results on tumour growth and core histone methylation when we replaced DZNep with the H3K27me3-specific-methylation inhibitor EPZ005687 (Fig. 7f-h ).
DISCUSSION
It is well established that the core of solid tumours is highly hypoxic and hypoxia is considered to be a major contributor to drug resistance 36 . However, whether nutrients are also depleted in regions of solid tumours similarly to oxygen is not clear. Here, we found that glutamine is dramatically decreased in the tumour core regions compared with the periphery (Fig. 1a and Table 1 ). Interestingly, a few other amino acids, including serine, asparagine, arginine and aspartic acid, are also significantly decreased in tumour core regions. A recent report demonstrated that glutamine, serine and asparagine are of the most strongly depleted metabolites in human pancreatic tumours 7 . This result is highly consistent with our data that those amino acids are significantly decreased in the tumour core probably due to the heavy usages and poor tumour blood supply (Table 1 and Supplementary  Table 1 ). It supports the hypothesis that amino acids that are consumed by multiple anabolic processes (such as glutamine and serine) become depleted in the tumour core regions relative to those used mainly for protein synthesis.
It is worth mentioning that, different from cultured cells, whether glutamine is a major source for αKG in vivo is likely to depend on both the tumour genotype and tissue of origin, similar to glucose metabolism 37 . For example, 13 C-glutamine tracing resulted in increased levels of TCA cycle metabolites in Myc-driven liver tumours 38 . In addition, analysis of NSCLC tumour metabolism in patients has indicated that both glucose and glutamine can be important for TCA anaplerosis 39, 40 . Nonetheless, a recent report demonstrated that glutamine is not a major source for αKG in KRasdriven lung tumours 41 . Here, we demonstrated that in V600E BRAF melanoma tumours, glutamine is sufficient to provide αKG in vivo (Fig. 1) . Interestingly, we found that the decrease in αKG levels in melanoma tumour core regions is more extensive than the decrease in glutamine levels (Supplementary Table 1 ), suggesting that other sources beside glutamine could also contribute to αKG levels in vivo, such as low glucose or hypoxia in tumour core regions.
Although H3K27me3 is associated with repressed transcription, accumulating evidence supports that H3K27me3 is essential for maintaining the self-renewal capability of embryonic and adult stem cells 8, 42 . In fact, it has been reported that critical genes involved in differentiation, such as HOX genes, are targeted for repression by H3K27 methylation 43 , supporting the hypothesis that H3K27me3 contributes to dedifferentiation by inhibiting transcription of differentiationrelated genes. Consistent with this model, we found that neural crest differentiation genes are directly repressed by this H3K27me3 methylation marker at promoter regions in melanoma cells (Fig. 6g) . This is consistent with the previous study showing that adipocyte differentiation genes such as Adipoq and Cebpa are suppressed by the binding of H3K9me3 and H3K27me3 at promoter regions 12 .
In addition, several reports demonstrated that the H3K27me3-specific methyltransferase EZH2 promotes cancer stem-like cell expansion 44, 45 . In agreement, our data demonstrate that EZH2 is required for low-glutamine-induced expression of dedifferentiation-related genes (Fig. 6e) .
Distinct tumour microenvironments may influence therapeutic responses mediated by inducing cancer cell dedifferentiation 46 . For example, depletion of oxygen in tumours contributes to cancer stemlike cells and promotes drug resistance, where it is usually located at tumour core or regions with a lack of blood vessels [47] [48] [49] [50] [51] . Consistently, our data showed another example that regional glutamine deficiency can also induce cancer cell dedifferentiation and lead to drug resistance (Fig. 5) . It is worth noting that other studies suggested that cancer stem cells that promote metastasis are located at the tumour P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e P e r i p h e r y C o r e 0 3 6 9 1 2 1 5 Figure 7 Low-glutamine-induced drug resistance is mediated by histone methylation on H3K27. (a) M229 or M249 cells were cultured in complete medium or 0.1 mM glutamine medium with the histone methylation inhibitors DZNep or EPZ005687 for 4 days, and then cells were treated with 1 µM PLX4032 for 3 days. MTS assay was performed to measure viability. Data represent mean ± s.d., n = 4 (M229), or n = 6 (M249) independent cell cultures. * * * P < 0.001 by unpaired two-tailed Student's t-test. (b) Control vector-and KDM6B shRNA lentiviral-transduced M229 bulk cells were treated with dimethylsulfoxide control or 1 µM PLX4032 for 72 h. MTS assay was performed to measure viability. Data represent mean ± s.d., n = 6 independent cell cultures. * * * P < 0.001 by unpaired two-tailed Student's t-test. (c) Control vector-and EZH2 shRNA lentiviral-transduced M229 bulk cells were treated with dimethylsulfoxide control or 1 µM PLX4032 for 48 h. MTS assay was performed after treatment. Data represent mean ± s.d., n = 5 independent cell culture. * * * P < 0.001 by unpaired two-tailed Student's t-test. Source data for a-c are shown in Supplementary 3 , mice were treated with vehicle control (n = 6 mice), DZNep (intraperitoneal (i.p.) injection 1.5 mg kg −1 , n = 4 mice), PLX4032 (oral gavage, 10 mg kg −1 , n = 5 mice), or both DZNep and PLX4032 (n = 5 mice) daily for 15 days. Tumour size was measured over time. The graph represents mean ± s.d., * * P < 0.01, * * * P < 0.001 by unpaired two-tailed Student's t-test. (e) Samples from peripheral or core regions of the individual tumour as indicated were lysed and immunoblotting was performed with the indicated antibodies. Total H3 was used as a loading control. (f) Nude mice were injected subcutaneously with 5 × 10 6 M229 cells. When the tumour size reached an average of 100 mm 3 , mice were treated with vehicle control (n = 8 mice), EPZ005687 (i.p. injection, 2.5 mg kg −1 , n = 7 mice), PLX4032 (oral gavage, 10 mg kg −1 , n = 6 mice), or both DZNep and PLX4032 (n = 7 mice) every other day for 25 days. Tumour size was measured over time. The graph represents mean ± s.d. * P < 0.05, * * P < 0.01 by unpaired two-tailed Student's t-test. (g) Representative tumours in each group. (h) Samples from peripheral or core regions of the individual tumour as indicated were lysed and immunoblotting was performed with the indicated antibodies. Total H3 was used as a loading control. Unprocessed original scans of blots are shown in Supplementary Fig. 8 .
fronts or vascular niche [52] [53] [54] . It is not clear whether low-glutamineinduced dedifferentiation enhances metastatic potential. However, it is possible that low-glutamine/hypoxic regions will eventually result in VEGF expression and vascular formation over time, which will further provide other critical factors for cancer stem cell maintenance and metastasis, such as β-catenin, VEGF, Nrp1 and TGF [52] [53] [54] . In support of this, in the invasive front of pancreatic tumours, a distinct subpopulation of cancer stem cells was identified that determines the metastatic phenotype, but not the tumorigenic potential 55 . In the past few years, targeting EZH2 as a potential cancer therapy has been explored. However, understanding where and how EZH2 inhibitors will be useful in cancer therapy is critical for the use of these drugs 56 . Our results provide the molecular basis for an important strategy to combine cancer drugs, such as BRAF inhibitor, with EZH2 inhibitor to achieve a more promising treatment efficacy.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper for two days; then the cells were maintained in the medium with 1 µg ml −1 insulin for two more days followed by changing the medium to regular DMEM with 10% FBS before harvesting two days later. Human adipocyte-derived stem cell differentiation was induced as previously described 60 . The differentiated cells were stained with 0.3% Oil-Red-O solution after 3.7% formaldehyde fixation. For quantification, isopropanol was added to the stained cells to dissolve Oil-Red-O, and absorbance was measured at 500 nm. 3D staining. Melanoma xenograft tumours were processed utilizing the Passive CLARITY Technique (PACT) methodology 18, 61 . Briefly, the intact xenograft tumours were fixed in 4% paraformaldehyde at 4 • C overnight and then rinsed in PBS and placed in 4% acrylamide solution for two days at 4 • C to generate hydrogelhybrid tissues with 0.25% w/v VA-044 added. The acrylamide-infused tissues were then polymerized after degassing and nitrogen backfilling the solutions by placing the tissues in a vial at 37 • C for 4 h until the bulk solution became viscous. The acrylamide-tissue hybrids were then cleared using 8% SDS for 5-7 days until clear. Tissues were then stained with primary antibody at room temperature at 1:100 dilution for two days, rinsed for one day in PBST (PBS + 0.05% Tween-20) and then placed in the fluorescent secondary antibody for two days. The tissues were rinsed for an additional day in PBST and then placed in RIMS-2 solution for one day. Tissues were imaged using a Zeiss 780 confocal microscope with a 5× or 10× objective. 3D maximal projection images were generated using IMARIS software. The antibodies used for the staining can be found in Supplementary Table 2 .
Metabolite extraction and mass spectrometry. Mice were euthanized by CO 2 asphyxiation followed by cervical dislocation. Tumours were harvested and placed on dry ice immediately. For most of the tumours, it took less than 5 min from euthanization to isolation of the tumour. Tumours were then kept in liquid nitrogen for two weeks before the peripheral and core tissues were isolated on dry ice. Right after isolation, the peripheral and core tissues were soaked in pre-cooled 80% methanol (−80 • ) in HPLC-grade water (1 ml 80% methanol per 100 mg sample) in dry ice, and then homogenized with Precellys 24 homogenizer and Precellys Ceramic kit. Homogenate (150 µl) was mixed with ice-cold 400 µl 80% methanol. After centrifugation at 4 • C, 500 µl polar extracts was transferred to a new 1.5 ml centrifuge tube and dried with a speed vacuum. The dried metabolite pellets were stored at −80 • C. Before mass spectrum analysis, the dried metabolite pellets were dissolved in mobile phase A (0.03% formic acid in water, 1 µl mobile phase A per milligram tumour tissue). Liquid chromatography-mass spectrometry (LC-MS) and data analysis were carried out at the Centre for Metabolomics and Mass Spectrometry at The Scripps Research Institute and Duke University 62 . For the cell culture sample preparation, medium were aspirated quickly from a 6-well plate and pre-cooled 80% methanol (−80 • ) was added to cover the cells. The plate with cells was incubated at −80 • for 15 min, and then the cells were scraped into extraction solvent. After centrifugation, the supernatant was collected and dried with a speed vacuum. Samples were sent to Duke University for LC-MS analysis.
RNA sequencing. mRNA deep sequencing was performed with the Illumina Hiseq2500. Sequencing libraries were prepared with TruSeq RNA Sample Preparation Kit V2 (Illumina) according to the manufacturer's protocol with minor modifications. Briefly, 500 ng of total RNA from each sample was used for polyadenylated RNA enrichment with oligo dT magnetic beads, and the poly (A) RNA was fragmented with divalent cations under elevated temperature. First-strand cDNA synthesis produced single-stranded DNA copies from the fragmented RNA by reverse transcription. After second-strand cDNA synthesis, the double-stranded DNA underwent end repair, and the 3 ends were adenylated. Finally, universal adapters were ligated to the cDNA fragments, and 10 cycles of PCR were performed to produce the final sequencing library. Library templates were prepared for sequencing using the cBot cluster generation system (Illumina) with TruSeq SR Cluster V3 Kit. Sequencing was performed in single-read mode of 40 cycles of read1 and 7 cycles of index read using the Illumina HiSeq 2500 platform with TruSeq SBS V3 Kits. Real-time analysis (RTA) software was used to process the image analysis and base calling. Sequencing runs generated approximately 40 million single reads for each sample.
Chromatin immunoprecipitation (ChIP). Cells were cultured in complete or 0.1 mM glutamine for 4 days and then harvested for ChIP analysis. In brief, 10 million cells were crosslinked with 1% formaldehyde for 5 min and quenched with 125 mM glycine for 5 min. After twice washing with PBS, cells were scraped and spun down in PBS. Cell pellets were resuspended in 0.5% SDS IP buffer and sonicated to generate 200-500 bp DNA fragments. After centrifugation, 25 µl magnetic beads and 1 µg antibody were added into 100 µl supernatant for each immunoprecipitation at 4 • C overnight. The next day, samples were washed with low-salt and high-salt buffer, LiCl immune complex buffer and TE buffer. Samples were incubated at 65 • C overnight to elute histone complexes. DNA was extracted by phenol/chloroform/isoamyl alcohol and precipitated by glycogen and ethanol. DNA was then used for qPCR analysis. The qPCR primers are listed in Supplementary  Table 2 .
Statistics and reproducibility. All western blot experiments were repeated at least three times with a representative gel being shown. For all other experiments, each was repeated independently at least two times with similar results. Results are shown as means; error bars represent standard deviation (s.d.). The unpaired two-tailed Student's t-test was used to determine the statistical significance of differences between means ( * P < 0.05, * * P < 0.01, * * * P < 0.001). Table 4 . All other data supporting the findings of this study are available from the corresponding author on request.
